Author:
Lu Eric,Hara Aki,Sun Shudong,Hallmark Brian,Snider Justin M.,Seeds Michael C.,Watkins Joseph C.,McCall Charles E.,Zhang Hao Helen,Yao Guang,Chilton Floyd H.
Abstract
AbstractPrevious research suggests that group IIA secreted phospholipase A2(sPLA2-IIA) plays a role in and predicts severe COVID-19 disease. The current study reanalyzed a longitudinal proteomic data set to determine the temporal (days 0, 3 and 7) relationship between the levels of several members of a family of sPLA2isoforms and the severity of COVID-19 in 214 ICU patients. The levels of six secreted PLA2isoforms, sPLA2-IIA, sPLA2-V, sPLA2-X, sPLA2-IB, sPLA2-IIC, and sPLA2-XVI, increased over the first 7 ICU days in those who succumbed to the disease. sPLA2-IIA outperformed top ranked cytokines and chemokines as predictors of patient outcome. A decision tree corroborated these results with day 0 to day 3 kinetic changes of sPLA2-IIA that separated the death and severe categories from the mild category and increases from day 3 to day 7 significantly enriched the lethal category. In contrast, there was a time-dependent decrease in sPLA2-IID and sPLA2-XIIB in patients with severe or lethal disease, and these two isoforms were at higher levels in mild patients. Taken together, proteomic analysis revealed temporal sPLA2patterns that reflect the critical roles of sPLA2isoforms in severe COVID-19 disease.
Publisher
Cold Spring Harbor Laboratory
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献